Raymond James analyst Ryan Deschner upgraded Dianthus (DNTH) to Strong Buy from Outperform with a price target of $123, up from $63. The firm is “increasingly bullish” on claseprubart following the Q4 update. The analyst increased the drug’s probability of success in chronic inflammatory demyelinating polyneuropathy to 80% citing the additional validation and progress of claseprubart in the Phase 3 CAPTIVATE CIDP pivotal study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks
- Dianthus price target raised to $130 from $100 at Clear Street
- Dianthus announces $400M common stock offering
- Dianthus price target raised to $98 from $81 at Jefferies
- Dianthus price target raised to $132 from $67 at Baird